OncoMatch/Clinical Trials/NCT06815497
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Is NCT06815497 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Telmisartan for ovarian cancer.
Treatment: Telmisartan — The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin)
Platinum-resistant or refractory ovarian cancer (OC) defined as progression of disease on carboplatin or growth of disease as detected on computed tomography (CT) scan within 6 months of last platinum treatment
Cannot have received: (rituximab, amifostine)
Received rituximab or amifostine within 30 days prior to first telmisartan dose on this study
Cannot have received: (bevacizumab)
Exception: as part of their SOC chemotherapy regimen
Using bevacizumab as part of their SOC chemotherapy regimen
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L, platelet count ≥100 x 10^9/L, hemoglobin ≥8 g/dL without recent transfusion (within 2 weeks)
Kidney function
creatinine ≤ 1.5 x IULN or measured or calculated creatinine clearance ≥ 40 mL/min per institutional standard
Liver function
total bilirubin level ≥1.5 x institutional upper limit of normal (IULN), AST ≤ 2.5 x IULN, ALT ≤ 2.5 x IULN
Adequate organ and bone marrow reserve function as indicated by the following: Adequate hematological function, defined as absolute neutrophil count (ANC) ≥1.5 x 10^9/L, platelet count ≥100 x 10^9/L, and hemoglobin ≥8 g/dL without recent transfusion (defined as a transfusion that has occurred within 2 weeks of the hemoglobin measurement); Adequate liver function, defined as total bilirubin level ≥1.5 x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) ≤ 2.5 x IULN, and alanine aminotransferase (ALT) ≤ 2.5 x IULN; Adequate renal function defined as creatinine ≤ 1.5 x IULN or measured or calculated creatinine clearance ≥ 40 mL/min per institutional standard. Assessment methods must be recorded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Hitchcock · Lebanon, New Hampshire
- Dartmouth-Hitchcock Manchester · Manchester, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify